Chongqing Derunsheng Pharmaceutical

Chongqing Derunsheng Pharmaceutical Co., Ltd. is a Chinese pharmaceutical company established in 2016 and based in Chongqing. Operating primarily under the Marketing Authorization Holder (MAH) model, the company focuses on the development, licensing, and wholesale distribution of pharmaceutical products, outsourcing its manufacturing to contract manufacturing organizations (CMOs). Its product portfolio includes Formoterol Fumarate Inhalation Solution for respiratory diseases like asthma and COPD, Glipizide Tablets for type 2 diabetes, and Omeprazole and Sodium Bicarbonate For Oral Suspension for gastrointestinal disorders. In early 2026, the company faced significant regulatory action when its Formoterol Fumarate Inhalation Solution was stripped of its national centralized procurement winning status due to GMP compliance failures identified during a regulatory inspection.